ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.693,46
0,06%
S&P 500
5.307,01
-0,27%
Dow Jones
39.671,04
-0,51%
Euro vs US Dollar
1,0841
0,15%
Bitcoin
69.720,39
0,89%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Lantern Pharma Inc (LTRN)

  7. Lantern Pharma Inc (LTRN) News

LTRN

Lantern Pharma (LTRN)

Lantern Pharma Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:LTRN
DatumZeitQuelleÜberschriftSymbolFirma
13/05/202407h30Business WireOregon Therapeutics et Lantern Pharma lancent une collaboration stratégique dans le domaine de l’intelligence artificielle pour optimiser le développement du XCE853, premier candidat médicament de sa catégorie, un puissant inhibiteur...NASDAQ:LTRNLantern Pharma Inc
09/05/202422h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LTRNLantern Pharma Inc
09/05/202422h02Business WireLantern Pharma Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:LTRNLantern Pharma Inc
06/05/202409h00Business WireOregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer MetabolismNASDAQ:LTRNLantern Pharma Inc
02/05/202413h30Business WireLantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
24/04/202414h00Business WireLantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug DevelopmentNASDAQ:LTRNLantern Pharma Inc
22/04/202414h12Business WireLantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and TaiwanNASDAQ:LTRNLantern Pharma Inc
18/03/202421h02Business WireLantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business HighlightsNASDAQ:LTRNLantern Pharma Inc
18/03/202412h12IH Market NewsAnticipation Builds on Wall Street for Federal Reserve’s Upcoming Policy Moves; WTI and Brent See UpticksNASDAQ:LTRNLantern Pharma Inc
15/03/202413h00Business WireLantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284NASDAQ:LTRNLantern Pharma Inc
11/03/202412h30Business WireLantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
05/03/202414h01Business WireLantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual ConferenceNASDAQ:LTRNLantern Pharma Inc
04/03/202414h01Business WireLantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development TimelinesNASDAQ:LTRNLantern Pharma Inc
01/03/202403h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
15/02/202414h01Business WireLantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor CancersNASDAQ:LTRNLantern Pharma Inc
19/01/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
17/01/202413h30Business WireStarlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical OfficerNASDAQ:LTRNLantern Pharma Inc
29/12/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
01/12/202312h02Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LTRNLantern Pharma Inc
01/12/202312h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
30/11/202314h00Business WireFDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)NASDAQ:LTRNLantern Pharma Inc
24/11/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
08/11/202322h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LTRNLantern Pharma Inc
08/11/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
08/11/202322h01Business WireLantern Pharma Reports Third Quarter 2023 Financial Results and Operational HighlightsNASDAQ:LTRNLantern Pharma Inc
01/11/202313h00Business WireLantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
20/10/202323h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
10/10/202314h00Business WireLantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
03/10/202314h00Business WireLantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in GlioblastomaNASDAQ:LTRNLantern Pharma Inc
25/09/202314h30Business WireLantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid TumorsNASDAQ:LTRNLantern Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:LTRN

Kürzlich von Ihnen besucht

USOTC
BRMSY
BR Malls Participacoes (PK)
BIT
P1YW22
NLBNPIT1YW22 20351221 99...
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten